Lundbeck Q3 2019 Financial Results
Eptinezumab has the potential to transform the treatment paradigm for
migraine prevention
*
15
Eptinezumab will serve a large underserved patient population
in a seriously debilitating disease
Eptinezumab provides a differentiated clinical profile
*
Rapid onset of prevention by Day 1 driven by IV
formulation and 100% bioavailability
*
*
*
*
Strong response rate data from two phase III studies
Good tolerability profile similar to placebo
Quarterly 30-minute administration: Potentially
increased compliance for improved outcome
Alternative for patients uncomfortable with self
injection
POWERFUL
≥50%, ≥75% and
100% reductions in
migraine days
FAST
Onset of prevention
Day One post-infusion
SUSTAINED
for 3 months following
a single administration and
sustained or further
increased with
subsequent infusions
LundbeckView entire presentation